All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

TJ-L14B/ABL503 Showcases Early Efficacy Signals in Advanced or Metastatic Solid Tumors

October 10th 2023

TJ-L14B/ABL503 demonstrated preliminary efficacy signals in the form of responses in patients with progressive, locally advanced or metastatic solid tumors who were relapsed or refractory after previous lines of therapy.

Matching-Adjusted Analysis Shows Acalabrutinib/Obinutuzumab Offers PFS Benefit Vs Zanubrutinib in CLL/SLL Without 17p Deletions

October 10th 2023

Patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic leukemia without 17p deletions experienced superior efficacy following treatment with acalabrutinib plus obinutuzumab compared with zanubrutinib monotherapy.

Study Discovers a Mechanism for Genetic Changes in Therapy-Induced Leukemia, Builds on Fox Chase History of Exploring Links Between Epigenetics, Genetics, and Cancer

October 10th 2023

In a recent study, researchers at Fox Chase Cancer Center demonstrated how amplification and rearrangement of a gene associated with leukemia known as MLL is directly controlled by epigenetic factors, providing needed insights into a new therapeutic opportunity.

FDA Approves FoundationOne CDx Companion Diagnostic for Selpercatinib in RET+ Solid Tumors

October 10th 2023

The FDA has approved FoundationOne CDx for use as a companion diagnostic for selpercatinib, which was approved by the FDA for the treatment of adult patients with locally advanced or metastatic solid tumors harboring a RET gene fusion whose disease has progressed on or following prior systemic treatment, or who have no satisfactory alternative treatment options.

BXCL701 Plus Pembrolizumab Generates Positive OS Data in Small Cell Neuroendocrine mCRPC

October 10th 2023

Treatment with the combination of the investigational oral innate immune activator BXCL701 and pembrolizumab led to a median overall survival of 13.6 months in patients with small cell neuroendocrine carcinoma metastatic castration-resistant prostate cancer.

Marrying Career Interests

October 10th 2023

Professional and personal satisfaction are both possible with a hybrid option that optimizes work-life balance.

Perioperative Pembrolizumab Meets Dual Primary End Point of OS in NSCLC

October 10th 2023

Pembrolizumab plus chemotherapy prior to surgery, followed by resection and single-agent pembrolizumab in the adjuvant setting, significantly improved overall survival vs neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in patients with resectable stage II, IIIA, or IIIB (T3-4N2) non–small cell lung cancer, meeting the dual primary end point of the phase 3 KEYNOTE-671 trial.

Dual Inhibition With Bezuclastinib/Sunitinib Aims to Fill an Unmet Need in GIST

October 10th 2023

Combination therapy targeting multiple exons where mutations commonly develop in gastrointestinal stromal tumor may represent a promising treatment approach to increase efficacy when patients develop resistance to therapies such as imatinib.

Acalabrutinib Is Associated With Low Frequency of Cardiac Events Across 3 Randomized Trials in CLL

October 9th 2023

Administration of acalabrutinib to patients with chronic lymphocytic leukemia with or without cardiovascular disorders at baseline results in a numerically decreased incidence of overall treatment-related cardiac toxicities and a comparable safety profile vs comparator CLL therapies such as ibrutinib.

Continued Maintenance With Obinutuzumab Plus Acalabrutinib/Venetoclax Boosts uMRD Rate in R/R CLL

October 9th 2023

The undetectable minimal residual disease ate achieved with bendamustine followed by obinutuzumab, acalabrutinib, and venetoclax increased as the regimen was continued as maintenance treatment in patients with relapsed or refractory chronic lymphocytic leukemia.

Epcoritamab Monotherapy Demonstrates High Response Rates in High-Risk Relapsed/Refractory CLL

October 9th 2023

Treatment with subcutaneous epcoritamab-bysp elicited rapid and durable responses, including an encouraging complete response rate, and manageable safety in high-risk patients with relapsed/refractory chronic lymphocytic leukemia.

Pirtobrutinib Maintains Efficacy and Decreases BTK C481 Clones Despite Acquired Resistance Mutations in CLL

October 9th 2023

Patients with chronic lymphoctyic leukemia treated with pirtobrutinib monotherapy experienced comparable objective response rates regardless of acquired BTK mutation and a decrease or clearance of BTK cysteine 481 clones despite the emergence of non-C481 clones or other less common mutations during or near the time of progression.

Venetoclax and Rituximab Combination Maintains Survival Benefit in Relapsed/Refractory CLL

October 9th 2023

Patients with relapsed/refractory chronic lymphocytic leukemia achieved sustained progression-free survival and overall survival benefit after treatment with fixed-duration venetoclax plus rituximab vs bendamustine plus rituximab, according to data from the phase 3 MURANO trial.

Venetoclax Plus Dexamethasone Misses PFS End Point in t(11;14)+ R/R Multiple Myeloma

October 9th 2023

The combination of venetoclax and dexamethasone failed to significantly improve progression-free survival over pomalidomide plus dexamethasone in patients with t(11;14)-positive, relapsed or refractory multiple myeloma who have previously received at least 2 therapies.

Retrospective Analysis Sheds Light on Mutations Linked With BTK Inhibitor Resistance in CLL

October 8th 2023

Patients with chronic lymphocytic leukemia who experience disease progression during treatment with either covalent or noncovalent BTK inhibitors displayed a higher frequency of BTK mutations in L528W as well as RAS/RAF/MAPK pathway alterations, indicating that these alterations may play a role in the development of BTK inhibitor resistance.

Ibrutinib Cessation Following Prolonged Exposure Supports Intermittent Investigation in CLL

October 8th 2023

Stable peripheral disease levels lasting 12 months were reported in patients with treatment-naïve chronic lymphocytic leukemia following 6 years of continuous treatment with ibrutinib.

FDA Places Partial Clinical Hold on IND for Lacutamab in CTCL/PTCL

October 7th 2023

The FDA has placed a partial clinical hold on investigational new drug application for lacutamab, leading to a pause in new patient enrollment for the phase 2 TELLOMAK trial and a phase 1b trial, which are evaluating the agent in patients with advanced cutaneous T-cell lymphoma and peripheral T-cell lymphoma, respectively.

Radiotherapy-Activated NBTXR3 Elicits Activity in Older/Comorbid Locally Advanced HNSCC

October 6th 2023

Treatment with the first-in-class radioenhancer NBTXR3 proved tolerable and effective in older patients with advanced head and neck squamous cell carcinoma and a comorbidity index.

FDA Panel Votes Sufficient Evidence Available to Support EFS Benefit of Eflornithine in Pediatric High-Risk Neuroblastoma

October 6th 2023

In a 14-to-6 vote, the FDA’s Oncologic Drugs Advisory Committee voted sufficient evidence has been provided to demonstrate the event-free survival benefit of eflornithine to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma.

The Arsenal of Metastatic Breast Cancer Imaging Modalities Continues to Expand

October 6th 2023

Rena D. Callahan, MD, discusses the current standards for breast cancer imaging modalities, the complexities of using bone biopsy, and the importance of continuing to study nonstandard imaging modalities to increase the accessibility of breast cancer imaging for metastatic disease.